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Summary
We conducted a Cochrane systematic review on the effectiveness of supplemental intravenous crystalloid
administration in preventing postoperative nausea and vomiting. We included randomised controlled trials of
patients undergoing surgery under general anaesthesia and given supplemental peri-operative intravenous
crystalloid. Our primary outcomes were the risk of postoperative nausea and the risk of postoperative vomiting.
We assessed the risk of bias for each included study and applied the Grading of Recommendations,
Assessment, Development and Evaluations (GRADE) framework for the certainty of evidence. We included 41
studies. We found that the intervention probably reduces the overall risk of postoperative nausea, the risk ratio
(95%CI) being 0.62 (0.51–0.75) (I2 = 57%, p < 0.00001, 18 studies; 1766 participants; moderate-certainty
evidence). It also probably reduces the risk of postoperative nausea within 6 h of surgery, with a risk ratio (95%
CI) of 0.67 (0.58 to 0.78) (I2 = 9%, p < 0.00001, 20 studies; 2310 participants; moderate-certainty evidence) and
by around 24 h, the risk ratio (95%CI) being 0.47 (0.32–0.69) (I2 = 38%, p = 0.0001, 17 studies; 1682
participants; moderate-certainty evidence). Supplemental intravenous crystalloid probably also reduces the
overall risk of postoperative vomiting, with a risk ratio (95%CI) of 0.50 (0.40–0.63) (I2 = 31%, p < 0.00001, 20
studies; 1970 participants; moderate-certainty evidence). The beneﬁcial effect on vomiting was seen both
within 6 h andby around 24 hpostoperatively.
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Introduction
Postoperative nausea and vomiting (PONV) is a common
and unwelcome complication after general anaesthesia,
with important implications for patient satisfaction, surgical
outcomes and resource utilisation [1]. There are numerous
prophylactic treatments for PONV, such as ondansetron,
dexamethasone, tropisetron, dolasetron, cyclizine, granisetron
and droperidol. Pharmacological interventions are often
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used in combination [2], and multimodal prophylaxis is
recommended in patients predicted to be at high risk for
PONV [3]. The use of regional anaesthesia, or total
intravenous (i.v.) anaesthesia with propofol, is comparatively
protective against PONV [4–6]. Non-pharmacological
methods of PONV prophylaxis have also been described,
such as acupuncture [7].
Intravenous crystalloids are widely given peri-
operatively. They are inexpensive, have relatively few
adverse effects andmay offer another non-pharmacological
method of preventing PONV. A prior systematic review not
only reported that supplemental i.v. crystalloids may be
effective in preventing PONV but also suggested the
presence of reporting bias [1]. The goal of this review was to
systematically assess the effectiveness of supplemental i.v.
crystalloid administration in preventing PONV in patients
undergoing surgical procedures under general
anaesthesia, and also to assess potential harm of this
intervention. However, since PONV is inconsistently deﬁned
in the literature, we opted to focus on analysis of two related
outcomes, postoperative nausea and postoperative
vomiting, which are deﬁned more consistently in the
literature and are alsomore commonly reported.
Methods
A prospectively registered protocol for this systematic
review [8] and the unabridged Cochrane Review are
available elsewhere [9].
We included randomised controlled trials (RCT)
examining supplemental peri-operative i.v. crystalloid
administration, with participants older than 6 months,
undergoing any type of surgical procedure performed
under general anaesthesia. For sub-group and sensitivity
analyses, we deﬁned ‘children’ as aged between 6 months
and 17 years, and ‘adults’ as 18 years or older.
Given a lack of agreement in the literature on speciﬁc
volumes administered, we deﬁned the intervention as an i.v.
crystalloid volume larger than that received by a
comparator group. We included studies in which the
comparator received no supplemental peri-operative i.v.
crystalloid. We included studies regardless of the timing of
administration, including pre-operative, intra-operative,
postoperative or a combination of these. Timing of
administration was classiﬁed by the point at which
administration was initiated. We also included studies that
administered dextrose-containing crystalloids but, since i.v.
dextrose may independently reduce PONV [10], we
planned a sensitivity analysis to explore the effect of
including these studies on the meta-analysis. We excluded
other routes of crystalloid administration (i.e. oral). We
excluded studies that compared only supplemental i.v.
colloids with a comparator; however, we included studies
that used both colloids and crystalloids, as long as they had
an intervention group receiving only supplemental
crystalloid, in a volume greater than that received by a
comparator group that also received only crystalloid.
Our primary outcomes were: risk of postoperative
nausea (deﬁned as the presence of subjective nausea,
reported dichotomously or based on a study-deﬁned
dichotomous threshold on a continuous scale such as a
visual analogue scale); and risk of postoperative vomiting
(reported dichotomously by any discrete episodes of
vomiting). Although for both primary outcomes our
analyses focused on the risk of these outcomes over the
overall study period, when the data were available we also
analysed the risk of these outcomes occurring at different
time periods postoperatively (i.e., ‘early’ and ‘late’). In
accordance with the prior systematic review on this topic,
we deﬁned the early postoperative period as the time
period reporting the highest incidence of nausea or
vomiting within 6 h after surgery, and deﬁned the late
postoperative period as the timeperiod reporting nausea or
vomiting nearest to 24 h after surgery [1]. For the risk of
postoperative nausea, when continuous data were reported
(i.e. using a visual analogue scale), we also analysed them
separately from dichotomous data in order to better
characterise the magnitude of effect. Our secondary
outcomes were: risk of requiring pharmacological
treatment for PONV; risk of unplanned postoperative
admission to hospital; and risk of a serious adverse event
(i.e. admission to high-dependency unit, postoperative
cardiac or respiratory complication, or death).
Our detailed search strategy can be found in the
Supporting Information (Appendix S1). We searched the
following databases for relevant trials: Cochrane Central
Register of Controlled Trials; MEDLINE; Embase;
Cumulative Index of Nursing and Allied Health; and also
searched the relevant grey literature, and conducted
forward and backward searches through our references.
When necessary, we attempted to contact trial authors for
additional information. Our search was completed on 4
August 2018. We did not exclude any study based on
language of publication or publication status.
Two review authors (KJ, MW) read titles and abstracts,
removed obviously irrelevant reports and assessed the
retained studies using the Cochrane ‘Risk of Bias’ tool [11, 12].
Disagreements were resolved by discussion with two other
authors (RG, SB). Four authors (KJ, MW, RG, SB) examined the
full-text reports to determine which met the eligibility criteria,
andmade ﬁnal decisions on study inclusion.
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We assessed the certainty of the evidence based on the
Grading of Recommendations, Assessment, Development
and Evaluations (GRADE) approach [13, 14]. This approach
takes into consideration within-study risk of bias
(methodological quality), the directness of the evidence, the
heterogeneity of the data, the precision of effect estimates
and the risk of publication bias. We considered the
following standard methodological criteria: random
sequence generation (selection bias); allocation
concealment (selection bias); blinding of participants and
personnel (performance bias); blinding of outcome
assessment (detection bias); incompleteness of outcome
data (attrition bias); selective outcome reporting (reporting
bias); and other sources of bias.
We analysed data with ReviewManager 5 software [12],
using random-effects models for all comparisons, given the
anticipated moderate to high amount of heterogeneity
across studies [12, 15, 16]. Compared with ﬁxed-effects
models, random-effects models are more resistant to
ﬁnding spurious effects in the face of statistical
heterogeneity. We did not treat medians and means as
equivalent. When possible, we calculated missing statistics
from other quoted statistics. When participant dropout was
encountered, we used an intention-to-treat analysis. We
presented dichotomous data as risk ratios (RRs) along with
their 95%CIs, and continuous data as mean differences
(MDs) with 95%CIs.
We considered clinical heterogeneity during
manuscript evaluation, before pooling the results. We
quantiﬁed statistical heterogeneity using the I2 statistic,
judging the amount of heterogeneity as low (I2 < 40%),
moderate (I2 = 40–75%) or high (I2 > 75%) [13, 15, 17]. In
the event of moderate or high statistical heterogeneity, we
started with visual inspection of the forest plots, then
proceeded with the following a priori sub-group analyses,
namely: volume of supplemental i.v. crystalloid
administered (control:intervention volume ratio of less than
1:3 or greater than 1:3); timing of supplemental i.v.
crystalloid administration (pre-operative, peri-operative or
postoperative); and patient age (6 months to 17 years,
18 years or older). For outcomes that had a moderate or
high level of heterogeneity after sub-group analyses, the
results of the sub-group analyses are only presented in a
narrative manner. For outcomes involving sufﬁcient studies
in children, the sub-group results for them are also
speciﬁcally reported, to elucidate this important source of
clinical heterogeneity, and to provide speciﬁc guidance for
clinicians workingwith this speciﬁc patient population.
We performed sensitivity analyses for outcomes
involving studies that used dextrose-containing ﬂuids, as
this is an intervention that may independently reduce the
risk of PONV [10]. Also, there were different speciﬁc
volumes of supplemental i.v. crystalloid administered in
each study. We therefore conducted sensitivity analyses to
determine the effect of including studies that infused larger
absolute volumes of supplemental i.v. crystalloid to their
respective comparator groups (i.e. 10 ml.kg1 or more). We
additionally sought to assess the inﬂuence of studies at
relatively higher risk of bias. For each outcome involving
studies with one or fewer domains at high or unclear risk of
bias, we performed a sensitivity analysis using only those
studies with low risk of bias. Finally, in order to assess
publication bias, we visually inspected funnel plots
generated in Review Manager 5 for each outcome [12, 18,
19].
Results
For detailed results, please refer to our original Cochrane
review [9]. Study search and selection are shown in Fig. 1.
Three studies meeting inclusion criteria did not report data
in sufﬁcient detail [20–22]. We were unable to obtain further
information from these authors, so we included 38 RCTs in
themeta-analysis, using data from4034 participants.
Details of studies meeting our inclusion criteria are
presented in Table 1. All studies enrolled participants
undergoing surgery with general anaesthesia, performed
on an ambulatory basis or with a short length of stay
(i.e. one day). Thirty-one studies only included patients
classiﬁed as ASA physical status 1 or 2 [20, 23–25, 27–31,
33–38, 40–44, 48–52, 54–58, 60]. One study speciﬁcally
selected participants at high risk for PONV [27], whereas all
other studies were inconsistent in their reporting of baseline
risk factors for PONV. Intervention groups were generally
administered at least 10 ml.kg-1 of i.v. supplemental
crystalloid. In aminority of studies, comparator groups were
administered an i.v. supplemental crystalloid bolus
comparable to this volume [25, 29, 32, 35, 37, 40, 41, 45, 53,
54, 58].
Figure 2 shows the risk of bias for each study. This was
generally low to moderate across all included studies, but
eight studies were at high risk of bias [20, 21, 42, 43, 47, 48,
56, 59]. Only three studies were at low risk of bias across all
domains [24, 40, 41], although nine studies had a single
domain at unclear risk of bias but were otherwise at low risk
of bias [23, 25, 27, 29, 33, 36, 45, 46, 49].
Thirty-two studies (3268 participants) assessed the risk
of postoperative nausea [20, 22–24, 26, 28–32, 34, 36, 37,
39, 41–43, 45–57, 59, 60], but three of them reported data in
insufﬁcient detail to be used in any analyses of this outcome
[20, 22, 27].
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Eighteen studies (1766 participants) reported
dichotomous data for risk of nausea during the overall study
period [23, 24, 26, 29, 32, 36, 39, 41, 43, 45, 46, 48–52, 54,
60]. Supplemental i.v. crystalloid decreased the risk of
nausea during the overall study period, with a risk ratio (95%
CI) of 0.62 (0.51–0.75; I2 = 57%, p < 0.00001, Fig. 3). The
moderate statistical heterogeneity could not be reduced by
our planned sub-group analyses. We downgraded the
certainty of this evidence to ‘moderate’ due to risk of
publication bias, as indicated by funnel plot inspection. One
study (30 participants) used a dextrose-containing solution
in the intervention group [52], and a sensitivity analysis
found that inclusion of this study did not substantially affect
the risk ratio or the statistical heterogeneity. Additional
planned sensitivity analyses of studies at low risk of bias [23,
24, 29, 36, 41, 46, 49], and of studies administering
comparator groups at least 10 ml.kg-1 of supplemental i.v.
crystalloid [29, 32, 41, 45, 54] also did not substantially
affect the risk ratio.
Details of results for dichotomous data during speciﬁc
time periods and for continuous data across all time
periods, as well as their respective sensitivity analyses, are
all available in the full Cochrane review [9]. In summary,
supplemental peri-operative i.v. crystalloids decreased the
risk of nausea during both early and late time periods. The
risk ratio (95%CI) for early nausea was 0.67 (0.58–0.78;
I2 = 9%, p < 0.00001), and the risk ratio (95%CI) for late
nauseawas 0.47 (0.32–0.69; I2 = 38%, p = 0.0001). For both
time periods, we downgraded the certainty of evidence to
‘moderate’ due to risk of publication bias, as indicated by
funnel plot inspection. There were no studies reporting
continuous data for overall postoperative nausea; however,
the mean difference (95%CI) for early nausea was 16.38
(21.81 to 10.96; I2 = 47%, p < 0.00001), and for late
nauseawas9.62 (14.91 to4.32; I2 = 71%, p = 0.0004).
Thirty-one studies (3105 participants) evaluated
postoperative vomiting [22–34, 36–39, 41, 45–51, 53–55,
57, 58, 60]; however, one study did not report sufﬁciently
detailed data to be included in our analyses [22]. Four
studies (500 participants) reported vomiting in children,
aged 6 months to 18 years [25, 33, 39, 58].
Twenty studies (1970 participants) provided data for
vomiting across all time points [23–28, 32, 33, 36, 38, 39, 41,
45, 48–51, 54, 58, 60]. Supplemental i.v. crystalloids
decreased the risk of vomiting over the overall study period,
with a risk ratio (95%CI) of 0.50 (0.40–0.63; I2 = 31%,
p < 0.00001, Fig. 4). We downgraded the certainty of this
evidence to ‘moderate’ due to risk of publication bias, as
indicated by funnel plot inspection. For children speciﬁcally,
the intervention also reduced the overall risk of vomiting,
Figure 1 PRISMA ﬂowdiagramof study screening for inclusion.
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Table 1 Details of studiesmeeting inclusion criteria.
Study
Participant characteristics Intervention characteristics
Age Procedure type Timing Comparatorgroup Interventiongroup(s)
Ali et al. [23] Adult Various Pre-operative RL 2 ml.kg1 RL 15 ml.kg1
Amireh et al. [24] Adult Laparoscopic
cholecystectomy
Pre-operative No crystalloidbolus RL 10 ml.kg1
Ashok et al. [25] Child Various Intra-operative RL 10 ml.kg1 RL 30 ml.kg1
Behdadet al. [26] Adult Otorhinolaryngological
surgery
Intra-operative RL 4 ml.kg1 RL 10 ml.kg1
Intra-operative — RL 20 ml.kg1
Bennett et al. [20] Adult Dental extractions Pre-operative NS 1–2 ml.kg1 NS 15 ml.kg1
Bhukal et al. [27] Adult Various Intra-operative NS 4 ml.kg1 NS 10 ml.kg1
Chaudhary et al. [28] Adult Open cholecystectomy Pre-operative RL 2 ml.kg1 RL 12 ml.kg1
Chauhan et al. [29] Adult Laparoscopic
gynaecological surgery
Pre-operative RL 10 ml.kg1 RL 30 ml.kg1
Chohedri et al. [30] Adult Various Pre-operative NS 2 ml.kg1 NS 20 ml.kg1
Cook et al. [31] Adult Laparoscopic surgery Pre-operative No crystalloidbolus RL 20 ml.kg1
Pre-operative — RL 20 ml.kg1 with
1 g.kg1 dextrose
Dagher et al. [32] Adult Otorhinolaryngological
surgery
Pre-operative RL 10 ml.kg1 RL 30 ml.kg1
Egeli et al. [21] Child Otorhinolaryngological
surgery
Postoperative No crystalloidbolus D5RL 60–120 ml.h1
Elgueta et al. [33] Child Otorhinolaryngological
surgery
Intra-operative RL 10 ml.kg1.h1 RL 30 ml.kg1.h1
Elhakimet al. [34] Adult Therapeutic abortion Intra-operative No crystalloidbolus RL 1000 ml
Goodarzi et al. [35] Child Strabismus repair Intra-operative RL 10 ml.kg1.h1 RL 30 ml.kg1.h1
Gwak et al. [36] Adult Various Intra-operative RL 6 ml.kg1.h1 RL 18 ml.kg1.h1
Hashish et al. [37] Adult Laparoscopic
gynaecological surgery
Pre-operative RL 10 ml.kg1 RL 30 ml.kg1
Heidari et al. [38] Adult Orthopaedic surgery Pre-operative No crystalloidbolus RL 10 ml.kg1
Heshmati et al. [39] Child Otorhinolaryngological
surgery
Intra-operative No crystalloidbolus RL 4 ml.kg1.h1
Holte et al. [40] Adult Laparoscopic
cholecystectomy
Pre-operative RL 15 ml.kg1 RL 40 ml.kg1
Ismail et al. [41] Adult Laparoscopic
cholecystectomy
Intra-operative RL 10 ml.kg1 RL 30 ml.kg1
Keane et al. [42] Adult Various Mixed No crystalloidbolus Intra-operative RL
1000 ml then
postoperativeD5W
1000 ml
Lambert et al. [43] Adult Laparoscopic
gynaecological surgery
Pre-operative No crystalloidbolus RL 900–1000 ml
Lee et al. [44] Adult Laparoscopic
cholecystectomy
Pre-operative RL 5 ml.kg1.h1 RL 30 ml.kg1.h1
Magner et al. [45] Adult Laparoscopic
gynaecological surgery
Pre-operative RL 10 ml.kg1 RL 30 ml.kg1
Maharaj et al. [46] Adult Laparoscopic
gynaecologic surgery
Pre-operative RL 2 ml.kg1 per hour fasted RL 3 ml.kg1 per hour
fasted
McCaul et al. [47] Adult Laparoscopic
gynaecological surgery
Intra-operative No crystalloidbolus RL 1.5 ml.kg1 per hour
fasted
Intra-operative — D5RL 1.5 ml.kg1 per
hour fasted
(continued)
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albeit to a lesser degree, with a risk ratio (95%CI) of 0.69
(0.57–0.85; I2 = 0%, p = 0.0004). There were insufﬁcient
studies to conduct sensitivity analyses for dextrose-
containing solutions. Neither sensitivity analysis for studies
at low risk of bias [23–25, 27, 33, 36, 41, 45, 49] nor for
studies administering comparator groups at least 10 ml.kg-1
of supplemental i.v. crystalloid substantially affected the risk
ratio.
Details of results for speciﬁc time periods are available
in the full Cochrane review [9]. In summary, the intervention
decreased the risk of postoperative vomiting in both early
and late time periods. The risk ratio (95%CI) for early
vomiting was 0.56 (0.41–0.76; I2 = 0, p = 0.0003), and the
risk ratio (95%CI) for late vomiting was 0.48 (0.29–0.79;
I2 = 0%, p = 0.004).
Twenty-three studies (2416 participants) contributed
to our analysis of the risk of requiring pharmacological
treatment for PONV [23, 25–29, 31–36, 40, 41, 45, 46, 48,
49, 51, 54, 56, 59, 60]. Supplemental i.v. crystalloids
decreased the risk of requiring pharmacological treatment
for PONV, with a risk ratio (95%CI) of 0.62 (0.51–0.76;
I2 = 40%, p < 0.00001, Fig. 5). We downgraded the
certainty of this evidence to ‘moderate’ due to risk of
publication bias, as indicated by funnel plot inspection.
Due to moderate statistical heterogeneity, we carried out
our planned sub-group analyses, but the risk ratio was not
affected in any of them. Inclusion of dextrose-containing
solutions did not substantially affect the ratio or statistical
heterogeneity.
For children speciﬁcally, supplemental i.v. crystalloid
administration did not reduce the risk of requiring
pharmacological treatment for PONV, with a risk ratio (95%
CI) of 0.81 (0.50–1.30; I2 = 0%, p = 0.38). Neither inclusion
of studies administering comparator groups at least
10 ml.kg-1 of supplemental i.v. crystalloid [25, 29, 32, 33, 35,
40, 41, 45, 54], nor of studies at low risk of bias [23, 25, 27,
29, 33, 36, 40, 41, 45, 46, 49] substantially affected the risk
ratio.
Table 1 (continued)
Study
Participant characteristics Intervention characteristics
Age Procedure type Timing Comparatorgroup Interventiongroup(s)
Monti et al. [48] Adult Laparoscopic
gynaecological surgery
Pre-operative No crystalloidbolus RL 1000 ml
Murshed et al. [49] Adult Laparoscopic surgery Pre-operative RL 1.5 ml.kg1 per hour fasted RL 15 ml.kg1
Najaﬁanaraki [50] Adult Cervical cerclage Pre-operative RL 2 ml.kg1 per hour fasted RL 2 ml.kg1 per hour
fasted then
RL 10 ml.kg1
Onyando [51] Adult Various Pre-operative No crystalloidbolus RL ‘maintenance’ rate
per hour fasted
(maximum1000 ml)
Ooi et al. [52] Adult Therapeutic abortion Pre-operative No crystalloidbolus 4%dextrose/0.18%
saline solution
20 ml.kg1
Paganelli [53] Adult Laparoscopic
cholecystectomy
Intra-operative NS 10 ml.kg1.h1 NS 1000 ml bolus then
10 ml.kg1.h1
Sharmaet al. [54] Adult Laparoscopic
cholecystectomy
Pre-operative RL 10 ml.kg1 RL 20 ml.kg1
Pre-operative — RL 30 ml.kg1
Shin et al. [55] Mixed Various Pre-operative RL 2 ml.kg1 RL 20 ml.kg1
Singh et al. [22] Adult Various Pre-operative No crystalloidbolus RL 30 ml.kg1
Soleimani et al. [56] Adult Breast cancer surgery Pre-operative NS 1.5 ml.kg1.h1 NS 1.5 ml.kg1.h1 then
RL 5 ml.kg1
Intra-operative — NS1.5 ml.kg1.h1 then
RL 5 ml.kg1
Spencer [57] Adult Various Intra-operative No crystalloidbolus RL 1000 mL
Yilmaz [58] Child Otorhinolaryngological
surgery
Intra-operative NS 10 ml.kg1.h1 NS 20 ml.kg1.h1
Yogendran et al. [59] Adult Various Pre-operative Plasmalyte 2 ml.kg1 Plasmalyte 20 ml.kg1
Yoon et al. [60] Adult Various Intra-operative RL 2 ml.kg1 RL 18 ml.kg1
D5RL, dextrose 5% in Ringer’s Lactate; D5W, dextrose 5% inwater; NS, normal saline; RL, Ringer’s lactate.
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Three studies (235 participants) reported the rate of
unplanned admission to hospital after ambulatory surgery
[23, 31, 46]. The intervention did not affect this outcome,
where the risk ratio (95%CI) was 1.05 (0.77–1.43; I2 = 0%,
p = 0.77). We downgraded the certainty of this evidence
to ‘low’ due to imprecision and inconsistency of the
results. There were insufﬁcient studies for sensitivity
analyses.
No studies reported risks of serious adverse events.
Discussion
In summary, we found 41 trials (4224 participants) that met
our inclusion criteria, of which 38 trials (4034 participants)
contributed to our meta-analysis. We found that supple-
mental peri-operative i.v. crystalloid administration proba-
bly reduces the risk of both nausea and vomiting in the
overall postoperative period, as well as during early and late
time periods. The certainty of the evidence for postopera-
tive nausea and postoperative vomiting outcomes, assessed
using GRADE, is rated as ‘moderate’. Additionally, moder-
ate-certainty evidence suggests that the intervention proba-
bly reduces the risk of needing treatment with anti-emetic
rescue medication. There is low certainty evidence suggest-
ing the intervention does not inﬂuence the risk of unin-
tended postoperative hospital admission after ambulatory
surgery. No studies reported serious adverse events with
this intervention (i.e. admission to high-dependency unit,
postoperative cardiac or respiratory complication, or
death).
Before this meta-analysis, the most comprehensive
review of supplemental i.v. crystalloid administration for
PONV prophylaxis included 15 RCTs [1]. The results of that
review demonstrated statistically signiﬁcant decreases in
early, late and overall postoperative nausea, overall
postoperative vomiting, late and overall PONV and
postoperative antiemetic administration. Pooled effect sizes
for early and late vomiting, and early PONV, had suggested
a risk reduction but 95%CIs could not rule out a type-1 error.
Our meta-analysis furthers the work undertaken in that
review. By identifying new publications and completing a
thorough grey literature search up to August 2018, we have
included 26 additional studies, more than doubling the
number of participants. This allowed for a more highly
powered analysis with greater precision than the previous
meta-analysis. Improved power also likely explains why
some outcomes, speciﬁcally early and late vomiting, were
found to have signiﬁcant risk reductions, when this was not
the case in the prior analysis [1].
Figure 2 Risk of bias of included studies. Green: low risk of
bias; red: high risk of bias; yellow: risk of bias uncertain from
trial report.
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Most trials enrolled only ASA physical status 1 and 2
patients, for ambulatory or short length of stay procedures
(i.e. one day). Otherwise, there was signiﬁcant diversity
among the included studies. Trials took place in a number of
countries across the developed, emerging and developing
world. Participants underwent a wide range of surgical
procedures. Anaesthetic technique was varied, including
induction and maintenance agents, use of muscle relaxants
Figure 3 Forest plot of effect of supplemental peri-operative intravenous crystalloids on risk of postoperative nausea, during
overall postoperative period. 110 mg.kg1 intervention. 220 mg.kg-1 intervention. 330 mg.kg-1 intervention.M-H,
Mantel–Haenszel.
Figure 4 Forest plot of effect of supplemental peri-operative intravenous crystalloids on risk of postoperative vomiting, during
overall postoperative period. 110 mg.kg1 intervention. 220 mg.kg1 intervention. 330 mg.kg1 intervention;M-H,
Mantel–Haenszel.
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and reversal agents, opioid administration and
pharmacological PONV prophylaxis. Participants’ baseline
risk of PONV probably varied between studies, but this
information was insufﬁciently reported for us to conﬁrm.
Although such variation probably introduced heterogeneity
into the results, it also suggests that our conclusions are
generalisable to a sizeable scope of ambulatory surgical
populations.
We found that PONV was very inconsistently deﬁned
across studies. This challenge led us to focus instead
on the related outcomes of postoperative nausea and
postoperative vomiting, which are more precisely and
consistently deﬁned. Most trials included in this review
reported on one of our primary outcomes (i.e. risk of nausea,
or risk of vomiting). There were few studies reporting
continuous data for risk of postoperative nausea, so far
fewer studies and patients were pooled for these data, but
wewere still able to assess how nausea severity was affected
by supplemental i.v. crystalloid administration.
Very few studies examined potential harm that
patients may experience from vigorous administration of
i.v. ﬂuid. For instance, no studies examined the risk of
serious adverse events, or the risk of prolonged length of
stay in the recovery area. This is clearly a deﬁciency in the
existing literature, as also demonstrated in prior systematic
reviews, [61] and warrants further investigation. Due to
differences in the way that studies deﬁned and reported
the volume of supplemental i.v. crystalloid that was
administered to patients, it was difﬁcult to compare
absolute volume administered across studies. Where
applicable, we conducted sub-group analyses of relative
supplemental i.v. crystalloid volume administered in
comparator and intervention groups, and we did not ﬁnd
this variable to be inﬂuential. Moreover, we conducted
sensitivity analyses omitting studies where comparator
groups received a volume of i.v. supplemental crystalloid
comparable to most studies’ intervention groups (i.e. at
least 10 ml.kg-1), and this appeared to have negligible
inﬂuence on the effect of the intervention. Optimal dosing
and timing for supplemental peri-operative i.v. crystalloid
administration remains unclear, and this presents an
obvious avenue for further clariﬁcation.
Most studies reported a consistent direction of effect,
with overlap of conﬁdence intervals, whereas pooled
Figure 5 Forest plot of effect of supplemental peri-operative intravenous crystalloids on risk of pharmacological treatment of
PONV, during overall postoperative period. 110 mg.kg1 intervention. 220 mg.kg1 intervention. 330 mg.kg1 intervention.
4Ringer’s lactate/dextrose intervention. 5Ringer’s lactate intervention. 6pre-operative intervention. 7postoperative intervention;
M-H,Mantel–Haenszel.
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participant numbers exceeded optimal effect size
calculations, so we did not downgrade any primary outcome
for imprecision [62]. Assessment of population, interventions
and outcomes of all included studies discovered no risk of
indirectness. We also completed a thorough grey literature
search; nonetheless, funnel plots for both primary outcomes
as well as risk of requiring pharmacological treatment for
PONV suggested a risk of publication bias.
There were some common pitfalls affecting the risk of
bias in this literature. For the majority of included studies,
there was insufﬁcient description of measures to ensure
random sequence generation and allocation concealment.
Similarly, the nature of the intervention and its timing made
it possible in many instances that blinding of participants
and personnel could have been compromised. However,
we performed sensitivity analyses of studies at low risk of
bias where possible, and it was reassuring that the inclusion
of studies at relatively higher risk of bias did not appear to
affect our estimate of risk in any outcome.
Despite these limitations, there are sufﬁcient data to
suggest that supplemental i.v. crystalloid administration
may be helpful to reduce the risk of PONV. The varied
settings do provide a degree of generalisability, albeit in an
ambulatory setting with generally healthy patients. These
results may not be easily generalised to sicker patients, or
more extensive operations where hospital length of stay is
expected to exceed one or twodays.
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